Company / Shareholders' Equity
Foghorn Therapeutics Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$45.5M
FY2025
5-year range
-$88.0M / $96.9M
FY2021-FY2025
Trend
+41.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Foghorn Therapeutics Inc. reports negative total equity of -$46M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$46M in FY2025.
Declined from $112,000 to -$46M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity increased 41.0% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$45.5M | +41.0% |
| FY2024 | -$77.2M | -69019.6% |
| FY2023 | $112.0K | -99.9% |
| FY2022 | $96.9M | +210.1% |
| FY2021 | -$88.0M | +0.0% |
| FY2020 | -$88.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026